Seagen Inc.
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Seattle Genetics, Inc. (to 2020)
41
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Dec 6 to 25, 2026 · next Dec 6
- 4 fees due Jan 7 to 16, 2027 · next Jan 7
- 2 fees due Feb 22 to 27, 2027 · next Feb 22
- 3 fees due Mar 1 to 26, 2027 · next Mar 1
- 5 fees due Apr 8 to 29, 2027 · next Apr 8
- 5 fees due May 5 to 28, 2027 · next May 5
- 2 fees due Jun 15 to 19, 2027 · next Jun 15
- 2 fees due Jul 2 to 26, 2027 · next Jul 2
- 2 fees due Aug 6 to 18, 2027 · next Aug 6
- 4 fees due Sep 1 to 26, 2027 · next Sep 1
- 2 fees due Oct 2 to 19, 2027 · next Oct 2
Recent changes
- 1 term has ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,345,785 | Treatment of renal cell carcinoma with anti-CD70 antibody-drug conjugates In force · From the USPTO record | In force | From the USPTO record | |
| US 9,428,585 | Humanized anti-CD70 binding agents and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,051,372 | Anti-CD70 antibody and its use for the treatment of cancer and immune disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 7,994,135 | Monomethylvaline Compounds Capable of Conjugation to Ligands In force · High confidence | In force | High confidence | |
| US 7,964,566 | Monomethylvaline Compounds Capable of Conjugation to Ligands In force · High confidence | In force | High confidence | |
| US 7,964,567 | Monomethylvaline Compounds Capable of Conjugation to Ligands In force · High confidence | In force | High confidence | |
| US 8,512,707 | Methods of treating drug-resistant cancers In force · From the USPTO record | In force | From the USPTO record | |
| US 7,750,116 | Antibody drug conjugate metabolites In force · From the USPTO record | In force | From the USPTO record | |
| US 7,695,716 | Methods of treating neoplastic, autoimmune and inflammatory diseases In force · From the USPTO record | In force | From the USPTO record | |
| US RE45,272 | β-glucuronide-linker drug conjugates In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 136: 3 patents in force now held by others · 24 lapsed for an unpaid fee · 38 ended at full term · 5 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
35 pending · 34 abandoned · 70 no status recorded